Pharmacological therapy of female urinary incontinence

African Health Sciences

Volumn 5, Issue 1, 2005, Pages 79-85

  Rizk, Diaa E E ^a,b  

^a UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

^b NONE   (United Arab Emirates)

Author keywords

Drugs; Pharmacology; Urinary incontinence; Women

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; CALCIUM ANTAGONIST; CAPSAICIN; CROMAKALIM; DARIFENACIN; DULOXETINE; EPHEDRINE; ESTROGEN; FLAVOXATE; IMIPRAMINE; MUSCARINIC RECEPTOR BLOCKING AGENT; NIFEDIPINE; OXYBUTYNIN; PHENYLPROPANOLAMINE; PHOSPHODIESTERASE INHIBITOR; PINACIDIL; PLACEBO; POTASSIUM CHANNEL STIMULATING AGENT; PROPANTHELINE BROMIDE; PROPIVERINE; PROSTAGLANDIN; PSEUDOEPHEDRINE; RESINIFERATOXIN; TERBUTALINE; TOLTERODINE; TROSPIUM CHLORIDE; UNINDEXED DRUG; VAMICAMIDE; VINPOCETINE; CHOLINERGIC RECEPTOR BLOCKING AGENT;

ABDOMINAL PAIN; ANTICHOLINERGIC SYNDROME; BLURRED VISION; CALCIUM TRANSPORT; CLINICAL TRIAL; CONSTIPATION; DETRUSOR DYSSYNERGIA; DISEASE SEVERITY; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG MECHANISM; ENZYME INHIBITION; EVIDENCE BASED MEDICINE; FEMALE; HEART PALPITATION; HUMAN; HYPERTENSION; INSOMNIA; LIVER TOXICITY; MUSCLE CONTRACTION; NONHUMAN; ORTHOSTATIC HYPOTENSION; PUBLIC HEALTH; QUALITY OF LIFE; REVIEW; SPASMOLYSIS; STRESS INCONTINENCE; TREMOR; URINE INCONTINENCE; XEROSTOMIA;

ADRENERGIC AGENTS; CHOLINERGIC ANTAGONISTS; FEMALE; HUMANS; URINARY INCONTINENCE;

EID: 33646041320     PISSN: 16806905     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Diokno AC. Epidemiology and psychosocial aspects of incontinence. Urol Clin North Am 1995; 22: 481-485.
2. Gosling JA, Dixon JS, Lendon RG. The autonomic innervation of the human male and female bladder neck and proximal urethra. J Urol 1977; 118; 302-305.
3. Hegde SS, Eglen RM. Muscarinic receptor subtypes modulating smooth muscle contractility in the urinary bladder. Life Sci 1999; 64: 419-428.
4. Portera SG, Lipscomb GH. Pharmacologic therapy for urinary incontinence and voiding dysfunctions. Clin Obstet Gynecol 1998; 41: 691-701.
5. Andersson KE, Appell R, Cardozo L, et al. The pharmacological treatment of urinary incontinence. Br J Urol Int 1999; 84: 923-947.
6. Andersson KE. Pharmacology of lower urinary tract smooth muscles and penile erectile tissues. Pharmacol Rev 1993; 45: 253-308.
7. Wall LL. Diagnosis and management of urinary incontinence due to detrusor instability. Obstet Gynecol Surv 1990; 45 (Suppl): 1-47.
8. Downie JW. Pharmacological treatment of incontinence and voiding disorders. Curr Opin Urol 1993; 3: 280-283.
9. Kroner BA, Garnett WR. Pharmacotherapy trials of urinary incontinence in the geriatric patient: a review of current literature findings. J Geriatr Drug Ther 1993; 7: 23-55.
10. Andersson K.E. Current concepts in the treatment of disorders of micturition. Drugs 1988; 35: 477-494.
11. Wein AJ. Pharmacology of incontinence. Urol Clin North Am 1995; 22: 557-577.
12. Madersbacher H, Stohrer M, Richter R, Burgdorfer H, Hachen HJ, Murtz G. Trospium chloride versus oxybutynin: a randomized, double-blind, multicentre trial in the treatment of detrusor hyper-reflexia. Br J Urol 1995; 75: 452-456.
13. Nilvebrant L, Hallen B, Larsson G. Tolterodine - A new bladder selective muscarinic receptor antagonist: preclinical pharmacological and clinical data. Life Sci 1997; 60:1129-1136.
14. Ruscin JM, Morgenstern NE. Tolterodine use for symptoms of overactive bladder. Ann Pharmacother 1999; 33: 1073-1082.
15. Wein AJ. Pharmacologic options for the overactive bladder. Urology 1998; 51 (Suppl): 43-47.
16. Yarker YE, Goa KL, Fitton A. Oxybutynin: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drugs Aging 1995; 6: 243-262.
17. Lipworth BJ. Clinical pharmacology of β3-adrenoceptors. Br J Clin Pharmacol 1996:43: 291-300.
18. Fantl JA, Bump RC, Robinson D, McClish DK, Wyman JF. Efficacy of estrogen supplementation in the treatment of urinary incontinence. Obstet Gynecol 1996; 88: 745-749.
19. Martin SW, Radley SC, Chess-Williams R, Korstanje C, Chapple CR. Relaxant effects of potassium-channel openers on normal and hyperreflexic detrusor muscle. Br J Urol 1997; 80: 405-413.
20. Mazur D, Wehnert J, Dorschner W, Schubert G, Herfurth G, Alken RG. Clinical and urodynamic effects of propiverine in patients suffering from urgency and urge incontinence. Scand J Urol Nephrol 1995; 29: 289-294.
21. Newgreen DT, Anderson CWP, Carter AJ, Naylor AM. Darifenacin - a novel bladder-selective agent for the treatment of urge incontinence. Neurourol Urodyn 1995; 14: 95-96.
22. Yamamoto T, Koibuchi Y, Miura S, et al. Effects of vamicamide on urinary bladder functions in conscious dog and rat models of urinary frequency. J Urol 1995; 154: 2174-2178.
23. Chancellor MB, De Groat W. Intravesical capsaicin and resiniferatoxin therapy: spicing up the ways to treat the overactive bladder. J Urol 1999; 162: 3-11.
24. Truss MC, Becker AJ, Uckert S, et al. Selective pharmacological manipulation of the smooth muscle tissue of the genitourinary tract: a glimpse into the future. Br J Urol Int 1999; 83 (Suppl 2): 36-41.
25. Thor KB, Katofiasc MA. Effects of duloxetine, a combined serotonin and norepinephrine re-uptake inhibitor, on central neural control of lower urinary tract function in the chloralose-anesthetized female cat. J Pharmacol Exp Ther 1995; 274: 1014-1024.
26. Millard RJ, Moore K, Rencken R, Yalcin I, Bump RC. Duloxetine vs placebo in the treatment of stress urinary incontinence: a four-continent randomized clinical trial. Br J Urol Int 2004; 93: 311-318.
27. Urinary incontinence in Adults Guideline Update Panel: Urinary incontinence in Adults: Acute and Chronic Management. Clinical practice Guideline, No.2, 1996 Update. Rockville, MD, Agency for Health Care Policy and Research, Public Health Service, US Department of Health and Human Services, 1996. AHCPR Publication No. 96-0682.